Ten (58.8%) of the 17 CDKN2A VUSs identified in a study of 638 patients with familial pancreatic cancer (Roberts et al., 2016) were found to be functionally deleterious in our assay and could be reclassified as likely pathogenic variants. The gene discussed is CDKN2A; the disease is pancreatic neoplasm.